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Abstract 
The cellular prion protein, termed PrPC, is a glycoprotein abundantly expressed in 
brains and to a lesser extent in non-neuronal tissues including lungs. It was reported 
that PrPC is expressed by lung epithelial cells in mice, and that it may play a protective 
role against lethal infection with influenza A viruses (IAVs). This may occur by 
regulating Cu content and superoxide dismutase activity, eventually reducing oxidative 
stress in infected lungs. Anti-oxidative therapeutics have been demonstrated to protect 
mice from lethal infection with IAVs. Therefore, PrPC might be a new target molecule 
for development of IAV therapeutics. Here, we introduce the anti-viral mechanism of 
PrPC against IAV infection and discuss perspectives of PrPC-targeting therapeutics 
against IAV infection. 
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Brief overview of prion protein 
The normal cellular isoform of prion protein, termed PrPC, is a glycoprotein anchored to the 
outer cell membrane via a glycosylphosphatidylinositol moiety [1,2]. It expresses most 
abundantly in brains, particularly by neurons [1,2]. It is also expressed in non-neuronal tissues 
including heart, lungs, and spleens as well as some in the immune system to a lesser extent 
[1,2]. Brain accumulation of the abnormally folded, amyloidogenic isoform, PrPSc, which is 
generated from PrPC through its conformational conversion, is essential in the pathogenesis of 
prion diseases [2]. These are a group of neurodegenerative disorders including 
Creutzfeldt-Jakob disease in humans and scrapie and bovine spongiform encephalopathy in 
animals [2]. Consistently, mice deficient for PrPC (Prnp0/0) have been shown to neither 
accumulate PrPSc in their brains nor develop prion diseases after inoculation with the 
infectious agents of these diseases, i.e. prions [3,4,5,6]. However, the exact function of PrPC 
remains elusive largely unknown. 
PrPC has been suggested to be involved in cell protective activities. Prnp0/0 mice 
developed enhanced neuronal cell apoptosis after ischemic brain injury [7,8,9]. PrP with a 
deletion of the N-terminally located octapeptide repeat (OR) region lost the protective activity 
to rescue Prnp0/0 neurons from ischemic brain injury [10]. This suggests that PrPC might have 
an anti-apoptotic role in neurons through the OR region, thereby protecting neurons from 
ischemia-induced apoptosis. Several lines of evidence indicate that PrPC could bind to Cu 
ions via histidine residues in the OR region [11,12,13]. Some investigators reported that Cu 
content and the enzymatic activity of Cu/Zn-dependent superoxide dismutase, or SOD1, are 
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lower in the brains of Prnp0/0 mice than in control wild-type (WT) mice [11,14,15]. Therefore, 
PrPC could play a role in delivery of Cu ions to cuproenzymes such as SOD1, thereby 
mitigating reactive oxygen species (ROS)-induced oxidative stress. This consequently exerts 
an anti-apoptotic activity through the OR region. Other neuronal functions have also been 
suggested for PrPC. Some investigators reported that electrophysiological activities such as 
GABA receptor-mediated fast transmission and long-term potentiation were impaired in 
hippocampal slices from Prnp0/0 mice [16]. This suggests a role for PrPC in learning and 
memory processes. However, normal GABA receptor-mediated fast transmission and 
long-term potentiation have been reported in Prnp0/0 hippocampus by others [17]. PrPC has 
also been suggested to play a role in long-term survival of cerebellar Purkinje neurons [18], 
regulation of chemoreceptor numbers at the neuromuscular junction [19], and in controlling 
circadian activity rhythms and sleep patterns [20]. Prnp0/0 mice were also reported to be 
vulnerable to ischemic injuries to their hearts and kidneys [21,22]. This indicates that PrPC 
could have a protective role against ischemic injuries in non-neuronal tissues as well. PrPC is 
also expressed in immune cells, including T-lymphocytes, natural killer cells, macrophages, 
and mast cells [23,24,25]. This suggests a role for PrPC in the immune system.  
It was recently reported that PrPC is expressed by lung epithelial cells, including 
alveolar type 1 (AT1) and 2 (AT2) cells and bronchiolar Clara cells in mice [26], and that PrPC 
could provide some protection against infection with influenza A viruses (IAVs) via the OR 
region, by controlling Cu content and SOD1 activity [26]. This eventually reduces oxidative 




Pathogenic role of ROS in IAV infection 
IAVs are enveloped, single-stranded negative-sense RNA viruses, causing seasonal epidemics 
of influenza. Influenza is an acute respiratory disease with fever, nasal secretions, cough, high 
temperature, aching joints, and general malaise [27]. IAV infection has been a great public 
health concern [27,28,29]. Tens of millions of people seasonally suffer from IAV infection. 
From 250,000 to 500,000 people, particularly the young and elderly and those with 
underlying chronic lung or cardiovascular diseases, eventually die from influenza or its 
complications worldwide each year.  
The pathogenic mechanism of the IAV infection-induced lung injuries has been 
extensively studied. It has been suggested that ROS could play a pivotal role in lung injury 
after infection with IAVs, by causing apoptosis in infected lung epithelial cells 
[30,31,32,33,34]. ROS are chemically reactive molecules that contain oxygen, including 
superoxide, hydrogen peroxide, and hydroxyl radical. ROS overproduced in response to IAV 
infection overly oxidizes proteins, lipids, and DNA [35,36,37,38]. This damages these 
molecules in host cells eventually contributing to the pathogenesis of IAV infections 
[35,36,37,38]. Indeed, it has been demonstrated that treatment with the anti-oxidative agent 
N-acetyl-L-cysteine markedly suppressed ROS in the lungs of mice infected with 
IAV/WSN/33 (H1N1) (hereafter referred to as IAV/WSN) and decreased mortality of the 
infected mice [39,40].  
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Numerous enzymes are involved in generation of ROS. These include 
mitochondrial electron transport chain complexes, nitric oxide synthase, cytochrome P450 
reductases, the nicotinamide adenine dinucleotide phosphate oxidase family (NOXs), and 
xanthine oxidase (XO) [32]. Mice deficient in NOX2 showed reduced lung injuries after 
infection with IAV/X-31 (H3N2) and IAV/Puerto Rico/8/34 (H1N1) (referred to as IAV/PR8) 
[33]. Allopurinol, an inhibitor of XO, also reduced mortality of mice after infection with 
IAV/Kumamoto/Y5/67(H2N2) (referred to as IAV/Kumamoto) [30]. These results suggest 
that NOX2 and XO could be major ROS-generating enzymes in IAV infected lungs. 
 Cells are also equipped with anti-oxidative mechanisms to balance cellular redox 
homeostasis [32]. The SOD family, which includes SOD1, Mn-dependent SOD (SOD2), and 
extracellular SOD (SOD3), is one of the major enzyme classes that catalyze ROS 
detoxification reactions [41]. Infection with IAV/WSN and IAV/chicken/Hubei/327/2004 
(H5N1) (referred to as IAV/Hubei) reduced SOD1 expression at mRNA and protein levels in 
lung epithelial cells [40,42]. SOD1 overexpression was then shown to decrease ROS 
production in infected lung cells [40,42]. Moreover, it was shown that treatment with SOD1 
that is conjugated with pyran polymer successfully decreased the mortality of mice after lethal 
infection with IAV/Kumamoto [31]. These results indicate that SOD1 may be one of the 
major anti-oxidative enzymes responding to IAV infection.  
Agents such as neuraminidase inhibitors are currently in clinical use. However, 
worldwide spread of IAVs resistant to these agents has raised health concerns about 
pandemics caused by these resistant IAVs among human populations [43,44,45]. Currently 
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available agents target the molecules encoded by IAVs, promoting the emergence of IAVs 
carrying mutations in the genes encoding the targeted molecules [43,44,45]. These resistant 
mutant IAVs may eventually propagate among human populations [43,44,45]. Agents 
targeting host molecules are considered not to induce resistant IAVs. Since NOX2, XO, and 
SOD1 are host molecules, the agents targeting these molecules might be plausible 
therapeutics for IAV infection.  
 
Protective activity of PrPC against IAV infection 
It was recently reported that, compared to control WT mice, Prnp0/0 mice were highly 
sensitive to intranasal infection with IAV/PR8, A/Aichi/2/68 (H3N2), and IAV/WSN, and 
showed markedly elevated morbidity and mortality [26]. IAV/PR8-infected Prnp0/0 lungs 
were more severely damaged than control WT lungs [26]. Inflammatory cells were more 
abundantly infiltrated, inflammatory cytokines were more highly produced, and virus titers 
were slightly but significantly higher in IAV/PR8-infected Prnp0/0 lungs than in control WT 
lungs [26]. AT2 and Clara cells in IAV/PR8-infected Prnp0/0 lungs exhibited higher apoptosis 
than those in control WT lungs [26]. In contrast, consistent with that AT1 cells in C57BL/6 
mice were intact after IAV/PR8 infection [46], AT1 cells were not damaged in 
IAV/PR8-infected Prnp0/0 and WT lungs [26]. PrPC was expressed by AT1 and AT2 cells and 
bronchiolar Clara cells [26]. These results indicate that PrPC could provide some protection 
against lethal infection with IAVs in mice probably by exerting anti-apoptotic activity in lung 
epithelial cells after IAV infection (Fig. 1). It was also shown that Tg(PrP∆OR)/Prnp0/0 mice, 
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which transgenically express mouse PrP with the OR region deleted on the Prnp0/0 
background [47], showed higher mortality after infection with IAV/PR8 [26]. This indicates 
that the OR region could play an important role for PrPC to provide its protective activity 
against IAV infection. 
 The highly pathogenic H5N1 family of avian IAVs also infect neurons, causing 
apoptotic cell death in infected neurons, eventually developing neurological symptoms [48]. 
PrPC is expressed in neurons more abundantly than in lung epithelial cells, suggesting that 
PrPC could also protect neurons from apoptosis after infection with H5N1 avian IAVs. For 
development of therapeutics against H5N1 avian IAVs, it is worthwhile to investigate whether 
or not PrPC could provide protection against H5N1 avian IAVs in lung epithelial cells as well 
as in neurons. 
 
Anti-oxidative activity of PrPC against IAV infection  
The OR region is considered to be a site for PrPC to bind to Cu ions and deliver them to 
SOD1, thereby controlling SOD1 activity, eventually reducing oxidative stress [11,14,15]. 
Consistent with this, Cu content and SOD1 activity in IAV/PR8-infected Prnp0/0 lungs were 
lower than those in control WT lungs [26]. In contrast, ROS levels were higher in 
IAV/PR8-infected Prnp0/0 and Tg(PrP∆OR)/Prnp0/0 lungs than in control WT lungs [26]. 
Furthermore, butylated hydroxyanisole, a ROS scavenger, decreased the mortality of Prnp0/0 
mice infected with IAV/PR8 to that of control WT mice [26]. These results indicate that the 
protective activity of PrPC against IAVs infection could be attributable to the anti-oxidative 
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activity of PrPC through regulating the content of Cu and consequently the activity of SOD1 
in infected lungs via the OR region (Fig. 1). It was also found that XO was more highly 
expressed in Prnp0/0 lungs than in control WT lungs after infection with IAV/PR8 [26]. 
Furthermore, the XO inhibitor allopurinol reduced the mortality of Prnp0/0 mice infected with 
IAV/PR8 [26]. These results suggest that the higher ROS production in IAV-infected Prnp0/0 
lungs could also be attributable to the higher expression of XO. The lower SOD1 activity in 
Prnp0/0 epithelial cells might fail to efficiently reduce oxidative stress during infection with 
IAVs, causing higher apoptosis of infected epithelial cells (Fig. 1). This eventually provoked 
stronger inflammatory responses leading to higher production of inflammatory cytokines in 
Prnp0/0 lungs and higher mortality of IAVs-infected Prnp0/0 mice.   
 
Future perspective 
Anti-oxidative treatments have been successful against IAV infection, protecting mice from 
lethal infection with IAVs [30,31,32,49]. Indeed, the XO inhibitor allopurinol and 
polymer-conjugated SOD1 reduced mortality of mice after infection with IAV/Kumamoto 
[30,31]. It was shown that PrPC could provide some protection against lethal infection with 
IAVs in mice through its anti-oxidative activity by regulating SOD1 [26], raising the 
possibility that PrPC could be a new target molecule for development of therapeutics against 
IAV infection. However, compared to WT lungs, Prnp0/0 lungs produced slightly higher titers 
of IAVs after infection with IAVs [26], indicating that PrPC might have only marginal effects 
on IAV replication. Thus, PrPC-targeting anti-oxidative therapeutics might be more effective 
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for treatment of IAV infection in combination with other therapeutics suppressing IAV 
replication.  
It has been reported that stress-inducible protein 1 (STI1) and anti-PrP antibodies 
interacted with PrPC and protected neurons from apoptosis induced by anisomycin [50,51]. 
The interaction with STI1 with PrPC was also shown to activate SOD [52]. Identification of 
the agents, which interact with PrPC and then activate SOD in the same way as STI1 and 
anti-PrP antibodies can, would be very useful for development of a new type of anti-oxidative 
therapeutic agent in IAV infection. This is currently under investigation in our laboratory. 
These agents might be safe for clinical use since they are not expected to induce 
drug-resistant IAVs.  
 
Executive summary 
Brief overview of prion protein 
 PrPC is a membrane glycoprotein and expressed most predominantly in brains and to a 
lesser extent in non-neuronal tissues including lungs.  
 PrPC has been suggested to be involved in various cellular functions. 
 It was recently found that PrPC is expressed by lung epithelial cells and has a protective 
activity against infection with IAVs by regulating Cu content and SOD1 activity.  
Pathogenic role of ROS in IAV infection 
 IAVs are enveloped, single-stranded negative-sense RNA viruses, causing great public 
health concern about seasonal epidemic outbreaks of influenza.  
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 ROS could have a pivotal role in lung injury after infection with IAVs.  
 NOX2 and XO could be major ROS-generating enzymes in IAV infection. 
 SOD1 could be one of the major anti-oxidative enzymes responding to IAV infection.  
 Anti-oxidative therapeutics targeting NOX2, XO, and SOD1 might be worthwhile to for 
consideration as a new type of therapeutic agent against IAV infection.  
Protective activity of PrPC against IAV infection 
 PrPC could provide a protection against lethal infection with IAVs in mice. 
 The OR region could be important for PrPC to exert its anti-apoptotic activity in lung 
epithelial cells after IAV infection.  
Anti-oxidative activity of PrPC against IAV infection  
 The protective activity of PrPC against IAV infection could be attributable to its 
anti-oxidative activity. 
 PrPC could regulate the Cu content and SOD1 activity in infected lungs through the OR 
region.  
Future perspective 
 PrPC could be a new target molecule for development of anti-oxidative therapies against 
IAV infection.  
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Figure 1. Possible mechanism for the protective role of PrPC against IAV infection. To 
establish infection, IAV particles attach lung epithelial cells, enter the cells through an 
endocytic pathway, and release the viral ribonucleoproteins from the endosome compartments 
into the cytoplasm. IAV infection leads to overproduction of ROS in lung epithelial cells, 
causing apoptosis of the cells. PrPC could play a protective role against IAV infection by 
reducing ROS levels through activating the anti-oxidative enzyme SOD1. PrPC binds to Cu 
ions through the OR region and delivers them to SOD1, thereby activating it. The activated 
SOD1 then reduces ROS levels in IAV-infected epithelial cells and eventually inhibits the cell 
from undergoing apoptosis.  
 
 
 

